Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Digma System First in Human (FIH) Study

NCT: NCT07331857 · RECRUITING

NCT IDNCT07331857
StatusRECRUITING
Start Date2026-05-25
Completion2027-12-31
SponsorDigma Medical Ltd. (INDUSTRY)
First posted
Last updated

Brief Summary

Prospective, open-label, single-arm, early feasibility study (EFS) in 2 Patient cohorts: Cohort A - Dose finding / Dose response study in patients with various etiologies undergoing Esophagectomy and Cohort B - Patients with Barrett's Esophagus (BE) with Low-Grade Dysplasia (LDG) or High-Grade Dysplasia (HGD) without a visible (excisable) lesion. This is a pilot study which plan to enroll up to 5 eligible patients in the First Cohort (A) and up to 15 patients in the Second Cohort (B) of the study.

Frequently Asked Questions

What is Digma System First in Human (FIH) Study?

Digma System First in Human (FIH) Study is a clinical trial registered under NCT07331857. Current status: RECRUITING.

What is the status of NCT07331857?

The current status of NCT07331857 (Digma System First in Human (FIH) Study) is: RECRUITING.

When did Digma System First in Human (FIH) Study start?

Digma System First in Human (FIH) Study started on 2026-05-25.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.